To the full analysis
Novavax stock: growth
NVAXNovavax reported $1.12B in revenue for fiscal 2025, up 64.7% on the prior year, up 18.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
33.4%
per year from 2006 to 2025, per share 8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 118.8% | 41.0% | 33.4% |
| Revenue per share | 77.9% | 9.6% | 8.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $4.68M | −$23.07M | −$16.33M |
| 2007 | $1.51M | −$34.77M | −$28.7M |
| 2008 | $1.06M | −$36.05M | −$30M |
| 2009 | $325K | −$38.37M | −$33.58M |
| 2010 | $343K | −$35.71M | −$34.41M |
| 2011 | $14.69M | −$19.36M | −$24.24M |
| 2012 | $22.08M | −$28.51M | −$22.57M |
| 2013 | $20.92M | −$51.98M | −$51.14M |
| 2014 | $30.66M | −$82.95M | −$74.28M |
| 2015 | $36.25M | −$156.94M | −$144.38M |
| 2016 | $15.35M | −$279.97M | −$273.68M |
| 2017 | $31.18M | −$183.77M | −$142.89M |
| 2018 | $34.29M | −$184.75M | −$186.2M |
| 2019 | $18.66M | −$130.1M | −$138.48M |
| 2020 | $22.39M | −$418.26M | −$97.16M |
| 2021 | $197.58M | −$1.74B | $265.46M |
| 2022 | $1.6B | −$657.94M | −$508.92M |
| 2023 | $556.38M | −$545.06M | −$772.77M |
| 2024 | $682.16M | −$187.5M | −$100.32M |
| 2025 | $1.12B | $440.3M | −$250.2M |
Revenue by region
Where Novavax, Inc. generates its revenue.
- Rest of North America51%
- United States36%
- Rest of the World11%
- Europe1%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Rest of North America | $4.46M | $575.67M | 51.2% |
| United States | $522.54M | $405.61M | 36.1% |
| Rest of the World | $59.02M | $126.46M | 11.3% |
| Europe | $96.14M | $15.74M | 1.4% |
| Total revenue | $682.16M | $1.12B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.